Adding to it, a study conducted by Sam et al. highlighted that glucagon-like peptide-1 (GLP-1), an agonist and a class of medication used to treat T2DM, improves pancreatic islet viability by upregulating HIF-1α through cAMP-mediated induction of the mTOR pathway [61]. Here, MTOR is linked to type 2 diabetes mellitus.